论文部分内容阅读
胃肠癌远远超过其它任何一个系统的发病率。以往17年只有氟脲嘧啶(5-FU)是晚期胃肠癌的最有效疗法,但此药只能使一小部分病人产生不完全的和暂时的瘤体缩小(常在15%～20%范围内)。没有发现其它单一药物超过或比得上氟脲嘧啶对胃肠癌病人达到的有限成就。因此,近来对药物联用的研究已给予更多的重视,着眼点在氟脲嘧啶与亚硝脲的联合应用上。亚硝脲:卡氮芥(BCNU),环己亚硝脲(CCNU)及甲基环己亚硝脲(Methyl-CCNU)的毒性基本相同且治疗谱非常类似。后二药可口服。各自单独在胃肠癌上应用时有效率比单用氟脲嘧啶小,常在10%～15%之间,且缓解期大约只有3个月。作者认为甲基环己亚硝脲是一种最好
Gastrointestinal cancer far exceeds the incidence of any other system. Only fluorouracil (5-FU) has been the most effective therapy for advanced gastrointestinal cancer in the past 17 years, but this drug can only cause incomplete and temporary tumor shrinkage (usually 15% to 20%) in a small proportion of patients. Range). No single drug has been found to exceed or match the limited success achieved by fluorouracil in patients with gastrointestinal cancer. Therefore, more attention has been paid to the study of drug combination recently, focusing on the combined use of fluorouracil and nitrosourea. Nitrosoureas: The BCNU, CCNU, and Methyl-CCNU have essentially the same toxicity and very similar spectrum of treatment. After the two drugs can be oral. Each of them is more effective than fluorouracil alone in the application of gastrointestinal cancer, and is usually between 10% and 15%, and the remission period is only about 3 months. The author believes that methylcyclohexyl nitrosourea is the best